Robert Yarchoan

Yarchoan Robert 250

Robert Yarchoan is Chief of the HIV and AIDS Malignancy Branch and Director of the Office of HIV and AIDS Malignancy in the National Cancer Institute. He played a major role in the development of the first effective therapies for HIV infection, including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). He also led the initial studies of these drugs and combination anti-HIV therapy. His research is now focused on AIDS-related malignancies, especially tumors caused by Kaposi's sarcoma-associated herpesvirus (KSHV). His team has developed effective therapies for Kaposi sarcoma and KSHV-associated multicentric Castleman disease, and has described a new KSHV-associated condition (KSHV inflammatory cytokine syndrome). In addition, his team investigated the biology of KSHV and pathogenesis of KSHV-relate diseases, including the important role of hypoxia-inducible factors (HIFs).